IndustryCompany release

Kiniksa raises 2026 ARCALYST sales guidance to about $1.05bn after 58% rise in Q3 revenue

🇺🇸 Kiniksa Pharmaceuticals International, plc (KNSA) · Tue 27 Oct 2026

The company reported $286.0m in third-quarter ARCALYST net revenue and lifted its full-year outlook, while confirming timelines for its KPL-387 and KPL-1161 pipeline programmes.

Kiniksa Pharmaceuticals International reported net revenue of $286.0 million for ARCALYST (rilonacept) in the third quarter of 2026, according to an announcement dated 27 October. The product is used in recurrent pericarditis, and the company put quarterly revenue growth at 58%.

Alongside the results, Kiniksa raised its full-year ARCALYST sales guidance to $1.045 billion–$1.050 billion. The previous range was $980 million–$995 million.

On market penetration, the company said about 23% of the roughly 14,000 patients per year who have multiple recurrences of pericarditis were on ARCALYST at the end of the quarter.

Kiniksa also gave an update on its pipeline. Pivotal Phase 3 data from the PASTORALE trial of KPL-387, a once-monthly subcutaneous IL-1 receptor antagonist antibody, are expected in the second half of 2027. A Phase 1 trial of a further candidate, KPL-1161, is due to begin by the end of 2026.

What it means for your team

  • Market-access teams can note the higher guidance and the stated 23% share of the multiple-recurrence pericarditis population, which indicates that much of the addressable group is still untreated with ARCALYST.
  • Regulatory and clinical teams should watch for PASTORALE Phase 3 data on KPL-387 in the second half of 2027, which would be the next pivotal readout in the company's IL-1 portfolio.
  • The planned start of the KPL-1161 Phase 1 trial by end-2026 is a further early-stage milestone to track.

Company's press release (SEC filing): Kiniksa Pharmaceuticals International, plc ↗

Article written by VigiEye from the official source (Kiniksa Pharmaceuticals International, plc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →